Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1065845 as Adjunctive Treatment in MDD
NCT06966401Phase 3Recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Apr 2025
- Primary completion
- May 2029
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of osavampator in major depressive disorder (MDD) and persistent depressive disorder (PDD), sponsored by Neurocrine Biosciences. Primary endpoint: Treatment-emergent Adverse Events at 52 weeks. Started Apr 2025; status: recruiting.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on NCT06966401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966401.